UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 220

Sortiert nach

Long-Acting HIV Drugs for Treatment and Prevention

Annual review of medicine, 2019-01, Vol.70, p.137

2019

Volltextzugriff (PDF)

Clinical Characteristics of Covid-19 in New York City

The New England journal of medicine, 2020-06, Vol.382 (24), p.2372-2374

2020

Volltextzugriff (PDF)

Raltegravir: The First HIV Type 1 Integrase Inhibitor

Clinical infectious diseases, 2009-04, Vol.48 (7), p.931-939

2009

Volltextzugriff (PDF)

Severe Covid-19

The New England journal of medicine, 2020-12, Vol.383 (25), p.2451-2460

2020

Volltextzugriff (PDF)

Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo

PloS one, 2009-05, Vol.4 (5), p.e5683-e5683

2009

Volltextzugriff (PDF)

Early versus Standard Antiretroviral Therapy for HIV-Infected Adults in Haiti

The New England journal of medicine, 2010-07, Vol.363 (3), p.257-265

2010

Volltextzugriff (PDF)

Pre-existing Minority Drug-Resistant HIV-1 Variants, Adherence, and Risk of Antiretroviral Treatment Failure

The Journal of infectious diseases, 2010-03, Vol.201 (5), p.662-671

2010

Volltextzugriff (PDF)

CCR5 Antagonism in HIV Infection: Current Concepts and Future Opportunities

Annual review of medicine, 2012-01, Vol.63 (1), p.81-93

2012

Volltextzugriff (PDF)

Safety, tolerability, and clinical outcomes of hydroxychloroquine for hospitalized patients with coronavirus 2019 disease

PloS one, 2020-07, Vol.15 (7), p.e0236778

2020

Volltextzugriff (PDF)

Mass spectrometry imaging of hair identifies daily maraviroc adherence in HPTN 069/ACTG A5305

PloS one, 2023-06, Vol.18 (6), p.e0287449-e0287449

2023

Volltextzugriff (PDF)

Phase 2 Study of the Safety and Efficacy of Vicriviroc, a CCR5 Inhibitor, in HIV-1-Infected, Treatment-Experienced Patients: AIDS Clinical Trials Group 5211

The Journal of infectious diseases, 2007-07, Vol.196 (2), p.304-312

2007

Volltextzugriff (PDF)

The Cost-effectiveness and Budget Impact of 2-Drug Dolutegravir-Lamivudine Regimens for the Treatment of HIV Infection in the United States

Clinical infectious diseases, 2016-03, Vol.62 (6), p.784-791

2016

Volltextzugriff (PDF)

Tissue specificity-aware TWAS (TSA-TWAS) framework identifies novel associations with metabolic, immunologic, and virologic traits in HIV-positive adults

PLoS genetics, 2021-04, Vol.17 (4), p.e1009464-e1009464

2021

Volltextzugriff (PDF)

Preexisting Resistance to Nonnucleoside Reverse-Transcriptase Inhibitors Predicts Virologic Failure of an Efavirenz-Based Regimen in Treatment-Naive HIV-1–Infected Subjects

The Journal of infectious diseases, 2008-03, Vol.197 (6), p.867-870

2008

Volltextzugriff (PDF)

Effect of CYP2B6, ABCB1, and CYP3A5 Polymorphisms on Efavirenz Pharmacokinetics and Treatment Response: An AIDS Clinical Trials Group Study

The Journal of infectious diseases, 2010-09, Vol.202 (5), p.717-722

2010

Volltextzugriff (PDF)

Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals

Annals of internal medicine, 2005-11, Vol.143 (10), p.714

2005

Volltextzugriff (PDF)

HIV Type 1 Chemokine Coreceptor Use among Antiretroviral-Experienced Patients Screened for a Clinical Trial of a CCR5 Inhibitor: AIDS Clinical Trial Group A5211

Clinical infectious diseases, 2007-02, Vol.44 (4), p.591-595

2007

Volltextzugriff (PDF)

No change in health-related quality of life for at-risk U.S. women and men starting HIV pre-exposure prophylaxis (PrEP): Findings from HPTN 069/ACTG A5305

PloS one, 2018-12, Vol.13 (12), p.e0206577-e0206577

2018

Volltextzugriff (PDF)

Pharmacogenetics of Plasma Efavirenz Exposure after Treatment Discontinuation: An Adult AIDS Clinical Trials Group Study

Clinical infectious diseases, 2006-02, Vol.42 (3), p.401-407

2006

Volltextzugriff (PDF)

Barriers to Uptake of Long-Acting Antiretroviral Products for Treatment and Prevention of Human Immunodeficiency Virus (HIV) in High-Income Countries

Clinical infectious diseases, 2022-11, Vol.75 (Suppl 4), p.S541-S548

2022

Volltextzugriff (PDF)

In Vivo Emergence of Vicriviroc Resistance in a Human Immunodeficiency Virus Type 1 Subtype C-Infected Subject

Journal of Virology, 2008-08, Vol.82 (16), p.8210-8214

2008

Volltextzugriff (PDF)

Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117

Nature (London), 2015-06, Vol.522 (7557), p.487-491

2015

Volltextzugriff (PDF)

Sex-Based Differences in Saquinavir Pharmacology and Virologic Response in AIDS Clinical Trials Group Study 359

The Journal of infectious diseases, 2004-04, Vol.189 (7), p.1176-1184

2004

Volltextzugriff (PDF)

Investigational Antiretroviral Drugs: What is Coming Down the Pipeline

Topics in antiviral medicine, 2018-04, Vol.25 (4), p.127-132

Gulick, Roy M

2018

Volltextzugriff (PDF)

1 – 25 von 220

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(200)
Mit Volltextzugriff
(156)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(158)
Humans
(153)
Life Sciences & Biomedicine
(146)
Infectious Diseases
(127)
Hiv Infections - Drug Therapy
(112)
Hiv
(105)
Male
(92)
Female
(86)
Immunology
(85)
Adult
(84)
Biological And Medical Sciences
(81)
Human Immunodeficiency Virus
(80)
Medical Sciences
(77)
Microbiology
(66)
Anti-Hiv Agents - Therapeutic Use
(65)
Viral Diseases
(65)
Human Viral Diseases
(62)
Viral Diseases Of The Lymphoid Tissue And The Blood. Aids
(60)
Virology
(60)
Hiv Infections - Virology
(58)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Long-Acting HIV Drugs for Treatment and Prevention

Clinical Characteristics of Covid-19 in New York City

Raltegravir: The First HIV Type 1 Integrase Inhibitor

Severe Covid-19

Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo

Early versus Standard Antiretroviral Therapy for HIV-Infected Adults in Haiti

Pre-existing Minority Drug-Resistant HIV-1 Variants, Adherence, and Risk of Antiretroviral Treatment Failure

CCR5 Antagonism in HIV Infection: Current Concepts and Future Opportunities

Safety, tolerability, and clinical outcomes of hydroxychloroquine for hospitalized patients with coronavirus 2019 disease

Mass spectrometry imaging of hair identifies daily maraviroc adherence in HPTN 069/ACTG A5305

Phase 2 Study of the Safety and Efficacy of Vicriviroc, a CCR5 Inhibitor, in HIV-1-Infected, Treatment-Experienced Patients: AIDS Clinical Trials Group 5211

The Cost-effectiveness and Budget Impact of 2-Drug Dolutegravir-Lamivudine Regimens for the Treatment of HIV Infection in the United States

Tissue specificity-aware TWAS (TSA-TWAS) framework identifies novel associations with metabolic, immunologic, and virologic traits in HIV-positive adults

Preexisting Resistance to Nonnucleoside Reverse-Transcriptase Inhibitors Predicts Virologic Failure of an Efavirenz-Based Regimen in Treatment-Naive HIV-1–Infected Subjects

Effect of CYP2B6, ABCB1, and CYP3A5 Polymorphisms on Efavirenz Pharmacokinetics and Treatment Response: An AIDS Clinical Trials Group Study

Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals

HIV Type 1 Chemokine Coreceptor Use among Antiretroviral-Experienced Patients Screened for a Clinical Trial of a CCR5 Inhibitor: AIDS Clinical Trial Group A5211

No change in health-related quality of life for at-risk U.S. women and men starting HIV pre-exposure prophylaxis (PrEP): Findings from HPTN 069/ACTG A5305

Pharmacogenetics of Plasma Efavirenz Exposure after Treatment Discontinuation: An Adult AIDS Clinical Trials Group Study

Barriers to Uptake of Long-Acting Antiretroviral Products for Treatment and Prevention of Human Immunodeficiency Virus (HIV) in High-Income Countries

In Vivo Emergence of Vicriviroc Resistance in a Human Immunodeficiency Virus Type 1 Subtype C-Infected Subject

Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117

Sex-Based Differences in Saquinavir Pharmacology and Virologic Response in AIDS Clinical Trials Group Study 359

Combination therapy with anti-HIV-1 antibodies maintains viral suppression

Investigational Antiretroviral Drugs: What is Coming Down the Pipeline

Suchergebnisse filtern